ZUBSOLV Drug Patent Profile

When do Zubsolv patents expire, and when can generic versions of Zubsolv launch?

Zubsolv is a drug marketed by Edenbridge Pharms and is included in one NDA. There are ten patents protecting this drug and four Paragraph IV challenges.

This drug has sixty-two patent family members in thirty-two countries.

The generic ingredient in ZUBSOLV is buprenorphine hydrochloride; naloxone hydrochloride. There are twenty-nine drug master file entries for this compound. Twenty-nine suppliers are listed for this compound. Additional details are available on the buprenorphine hydrochloride; naloxone hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Zubsolv

A generic version of ZUBSOLV was approved as buprenorphine hydrochloride; naloxone hydrochloride by ACTAVIS ELIZABETH on February 22^nd, 2013.

Summary for ZUBSOLV

International Patents:	62
US Patents:	10
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	5
Clinical Trials:	8
Patent Applications:	343
Drug Prices:	Drug price information for ZUBSOLV
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ZUBSOLV
What excipients (inactive ingredients) are in ZUBSOLV?	ZUBSOLV excipients list
DailyMed Link:	ZUBSOLV at DailyMed

See drug prices for ZUBSOLV

Recent Clinical Trials for ZUBSOLV

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Yale University	PHASE3
National Drug Abuse Treatment Clinical Trials Network	PHASE3
The Emmes Company, LLC	PHASE3

See all ZUBSOLV clinical trials

Pharmacology for ZUBSOLV

Drug Class	Opioid Antagonist Partial Opioid Agonist
Mechanism of Action	Opioid Antagonists Partial Opioid Agonists

Paragraph IV (Patent) Challenges for ZUBSOLV

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
ZUBSOLV	Sublingual Tablets	buprenorphine hydrochloride; naloxone hydrochloride	0.7 mg/0.18 mg	204242	1	2017-05-04
ZUBSOLV	Sublingual Tablets	buprenorphine hydrochloride; naloxone hydrochloride	2.9 mg/7.1 mg	204242	1	2015-12-21
ZUBSOLV	Sublingual Tablets	buprenorphine hydrochloride; naloxone hydrochloride	8.6 mg/2.1 mg and 11.4 mg/2.9 mg	204242	1	2015-07-24
ZUBSOLV	Sublingual Tablets	buprenorphine hydrochloride; naloxone hydrochloride	1.4 mg/0.36 mg and 5.7 mg/1.4 mg	204242	1	2013-10-22

US Patents and Regulatory Information for ZUBSOLV

ZUBSOLV is protected by ten US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Edenbridge Pharms	ZUBSOLV	buprenorphine hydrochloride; naloxone hydrochloride	TABLET;SUBLINGUAL	204242-003	Dec 11, 2014		RX	Yes	No			Y
Edenbridge Pharms	ZUBSOLV	buprenorphine hydrochloride; naloxone hydrochloride	TABLET;SUBLINGUAL	204242-002	Jul 3, 2013		RX	Yes	No			Y
Edenbridge Pharms	ZUBSOLV	buprenorphine hydrochloride; naloxone hydrochloride	TABLET;SUBLINGUAL	204242-004	Dec 11, 2014		RX	Yes	Yes			Y
Edenbridge Pharms	ZUBSOLV	buprenorphine hydrochloride; naloxone hydrochloride	TABLET;SUBLINGUAL	204242-004	Dec 11, 2014		RX	Yes	Yes			Y
Edenbridge Pharms	ZUBSOLV	buprenorphine hydrochloride; naloxone hydrochloride	TABLET;SUBLINGUAL	204242-004	Dec 11, 2014		RX	Yes	Yes			Y

Expired US Patents for ZUBSOLV

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Edenbridge Pharms	ZUBSOLV	buprenorphine hydrochloride; naloxone hydrochloride	TABLET;SUBLINGUAL	204242-003	Dec 11, 2014
Edenbridge Pharms	ZUBSOLV	buprenorphine hydrochloride; naloxone hydrochloride	TABLET;SUBLINGUAL	204242-006	Oct 4, 2016
Edenbridge Pharms	ZUBSOLV	buprenorphine hydrochloride; naloxone hydrochloride	TABLET;SUBLINGUAL	204242-001	Jul 3, 2013
Edenbridge Pharms	ZUBSOLV	buprenorphine hydrochloride; naloxone hydrochloride	TABLET;SUBLINGUAL	204242-005	Jun 4, 2015
Edenbridge Pharms	ZUBSOLV	buprenorphine hydrochloride; naloxone hydrochloride	TABLET;SUBLINGUAL	204242-004	Dec 11, 2014

International Patents for ZUBSOLV

When does loss-of-exclusivity occur for ZUBSOLV?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Cyprus

Denmark

European Patent Office

Japan

Poland

Portugal

Slovenia

Spain

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering ZUBSOLV around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2012311293
Australia	2013245546
Brazil	112014006356
Canada	2834327
Chile	2014000575

Supplementary Protection Certificates for ZUBSOLV

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2236132	C300714	Netherlands		PRODUCT NAME: ZOLPIDEM EN FARMACEUTISCH AANVAARDBARE ZOUTEN DAARVAN; NAT. REGISTRATION NO/DATE: RVG 108438 - 439 20130624; FIRST REGISTRATION: BE424286BE424295 2012180718
2236132	CA 2015 00004	Denmark		PRODUCT NAME: ZOLPIDEM OG FARMACEUTISK ACCEPTABLE SALTE HERAF, HERUNDER ZOLPIDEMTARTRAT; NAT. REG. NO/DATE: 47607 OG 47608 20120719; FIRST REG. NO/DATE: (B BE424286 OG BE424295 20120718
2236132	92636	Luxembourg		PRODUCT NAME: ZOLPIDEM ET SES SELS PHARMACEUTIQUEMENT ACCEPTABLES
2236132	122015000006	Germany		PRODUCT NAME: ZOLPIDEM UND PHARMAZEUTISCH VERTRAEGLICHE SALZE DAVON; NAT. REGISTRATION NO/DATE: 83439.00.00 83440.00.00 20120725 FIRST REGISTRATION: BELGIEN BE424286 BE424295 20120718
2236132	484	Finland

ZUBSOLV Market Dynamics and Financial Trajectory (2021–2026): Exclusivity, Competitive Pressure, Pricing, and Revenue Risk

Last updated: July 19, 2026

Zubsolv (buprenorphine and naloxone sublingual tablets) is a branded opioid use disorder (OUD) therapy competing in a constrained, high-switching market defined by Medicaid formularies, payer restrictions, and prescriber preferences shaped by product bioavailability and tablet count. Financial trajectory since 2021 has been dominated by continued conversion to generic buprenorphine/naloxone products, incremental share gains for competing branded products where payer coverage remains favorable, and ongoing pressure on net price from discounting and plan-level placement.

---

What is ZUBSOLV and how does it compete in opioid use disorder (OUD) markets?

ZUBSOLV product positioning: formulation and dosing

Zubsolv is a sublingual combination product for OUD containing buprenorphine (partial opioid agonist) and naloxone (opioid antagonist). Key commercial attributes that influence payer and prescriber adoption include:

• Sublingual dosing designed for patient adherence versus film formats
• Product size and perceived ease of use at comparable strength levels
• Switching risk driven by insurance coverage and pharmacist substitution (where permitted)

Where ZUBSOLV sits in the competitive set

Zubsolv competes against:

• Branded buprenorphine/naloxone sublingual tablets (including legacy branded products where coverage persists)
• Branded buprenorphine/naloxone films (pharmacy benefit incentives often favor film where acquisition cost is lower)
• Authorized generic and generic buprenorphine/naloxone products (strong formulary gravity after approvals and market entry)

---

How do payer dynamics and formularies drive ZUBSOLV market share?

Net price is a function of access

Zubsolv sales performance typically tracks payer access more tightly than pure demand generation due to:

• Closed formularies for “preferred” OUD products
• Prior authorization (PA) and step therapy
• Quantity limits that favor lower-cost equivalents
• Medicaid managed care contracting that can rapidly shift utilization

Medicaid and commercial insurance pressure

OUD patients are heavily concentrated in Medicaid and employer-sponsored plans with strong pharmacy benefit management. That mix produces:

• Faster erosion of branded shares after generic entry
• Price resets via PBM rebates and contracted discounts
• Increasing channel fragmentation across states and health plans

Formulary placement creates path dependency

Once a plan designates a product as preferred, switching patterns become sticky:

• Prescribers often continue what is reimbursed at the point of dispensing
• Pharmacies follow plan adjudication rules
• Patient stability on therapy reduces tolerance for switching unless coverage changes

---

When does ZUBSOLV lose exclusivity, and what does that mean for revenue timing?

Exclusivity timeline mechanics

For combo OUD products like buprenorphine/naloxone, branded longevity depends on a mix of:

• Regulatory exclusivity attached to listed reference products and specific labeling/dosage forms
• Patent estate strength around formulations, processes, and method-of-use (where applicable)
• Orange Book listings driving Paragraph IV leverage in generic litigation

Commercial impact of exclusivity erosion

In practice, revenue declines tend to accelerate when:

• Multiple strengths face generic substitution simultaneously
• Major PBMs or state Medicaid programs move to preferred generic equivalents
• Manufacturer support for contracting slows or becomes less effective

---

What patents protect ZUBSOLV, and how strong is the IP estate for blocking generic substitution?

Why ZUBSOLV’s IP matters commercially

For sublingual OUD products, generic entry is usually product-form substitution rather than a therapeutic class switch. That means IP strength affects:

• Time-to-market for generic competitors
• Whether generics launch “at-risk” into specific strengths
• Whether payer contracts remain viable for the branded manufacturer

IP risk categories that tend to drive challenges

Generic challenges usually target:

• Listed drug product patents (composition or formulation)
• Method-of-use patents tied to dosing regimens or treatment claims
• Manufacturing/process patents relevant to stability and delivery performance

No patent-number table is included here because the provided prompt contains no Zubsolv-specific Orange Book or litigation dataset.

---

What generic entry risks exist for ZUBSOLV, including Paragraph IV challenges?

How Paragraph IV dynamics impact sales

Paragraph IV certifications create a staged revenue risk profile:

• Pre-launch risk: market expects substitution; prescribers shift to stocked alternatives
• Launch risk: immediate price pressure and rebate re-sets
• Post-launch risk: branded share stabilizes only if coverage remains favorable for specific strengths

Strength-level and dosage-level substitution

Because OUD dosing is often titration-based, a plan’s coverage can change across:

• Initiation strengths versus maintenance strengths
• Tablet versus film availability
• NDC-level substitution rules at the pharmacy counter

---

How does ZUBSOLV compare with competing buprenorphine/naloxone products on market outcomes?

Branded vs generic: a practical revenue comparator

In OUD sublingual products, branded products often lose share rapidly once:

• Multiple generics become available for most strengths
• PBM contracts shift to lowest net cost
• State Medicaid formularies update

Tablet vs film competition

Film formulations can gain advantage from:

• Lower acquisition cost and rebate structures
• Patient preference trends within specific subpopulations
• Contracting preferences from PBMs

Zubsolv tablet-specific market traction depends on payer positioning and clinician preference for dosing experience.

---

How do litigation and settlements affect ZUBSOLV exclusivity and launch timing?

Litigation impacts are commercial, not abstract

In this category, litigation outcomes typically affect:

• Whether generics launch while branded remains in a “protected” strength set
• Whether settlement includes “carve-outs” for certain strengths or dosing forms
• Whether future patent challenges expand beyond initial claims

No litigation timeline is included because the prompt lacks Zubsolv-specific case identifiers and settlement terms.

---

What is the FDA regulatory status of ZUBSOLV, and how does it affect commercial scale?

Pathway relevance

OUD combo products are typically supported by:

• Established dosing label, REMS-adjacent compliance expectations, and pharmacy dispensing workflows
• Ongoing manufacturing compliance for stability and bioavailability
• Stability/quality updates that can affect supply continuity and payer confidence

Label changes and commercial sensitivity

Even small label updates can affect:

• Whether prescribers maintain current therapy
• Whether payers update PA criteria or coverage rules
• Whether substitution rules change at NDC granularity

No FDA milestone table is included because the prompt provides no Zubsolv NDA/BLA numbers, supplement history, or FDA labeling dates.

---

What formulations and strengths drive ZUBSOLV revenue exposure?

Revenue risk maps to strength mix

Revenue exposure is typically highest in:

• Widely used maintenance strengths
• Dosing tiers favored by payer formularies
• Geographies where contracted rebates keep branded net price within acceptable ranges

Tablet count and patient adherence

Sublingual patient adherence can influence persistence and re-fill rates, which then affects:

• Monthly prescription continuity
• Net sales stability in the face of partial generic substitution

---

How do manufacturing and supply constraints affect ZUBSOLV financial trajectory?

Supply stability is a sales multiplier in chronic therapy

For OUD therapies, stock-outs lead to:

• Immediate lost prescriptions
• Longer-term patient and prescriber migration to alternative products
• Restocking delays for pharmacies tied to distribution and contract status

Quality and compliance risk

Manufacturing changes can trigger:

• Temporary disruption if validated batches do not match prior performance
• Contract renegotiation if supply reliability slips

No Zubsolv-specific manufacturing events are listed because none were provided.

---

What are the key market financial indicators for ZUBSOLV (sales drivers and risks)?

Sales drivers

• Continued OUD patient demand and retention
• Payer access via preferred status or limited generic coverage
• Strength-specific pricing power where substitution is incomplete
• Prescriber continuity in stable patient cohorts

Sales risks

• Accelerating generic substitution and authorized generic penetration
• PBM rebate compression driven by competitive lowest-cost positioning
• Coverage restrictions that expand PA and step edits
• Supply disruptions or manufacturing batch validation delays

---

Revenue trajectory (2021–2026): what to expect in the absence of plan-level detail

Given the category economics of sublingual buprenorphine/naloxone products, a branded product’s financial trajectory typically follows this pattern:

• 2021–2022: lingering branded share from formulary inertia and incomplete substitution
• 2023–2024: intensified PBM and Medicaid contracting shifts toward lowest net cost; larger year-over-year net sales declines
• 2025–2026: stabilization only where contracting keeps branded as preferred for a meaningful NDC set; otherwise sustained erosion

No numeric revenue table is provided because the prompt does not include Zubsolv’s reported sales, segment disclosures, or SEC filings.

---

Key takeaways

• Zubsolv’s market dynamics are dominated by formulary access, not pure patient demand; net sales are sensitive to PBM contracting and Medicaid placement.
• The product faces persistent competitive pressure from generic buprenorphine/naloxone substitution across strengths and NDCs.
• IP and FDA-listed exclusivity affect revenue timing by influencing strength-level launch windows, but category economics favor generic diffusion once multiple strengths are exposed.
• Financial trajectory likely reflects a multi-year pattern of share erosion with partial stabilization only where payer contracts preserve branded net price.

---

FAQs

1. How quickly do generics typically replace Zubsolv after launch at major PBMs?
2. Which Zubsolv strengths are most exposed to substitution risk under Medicaid formularies?
3. Do tablet products like Zubsolv retain more share than film competitors in OUD?
4. How do PA requirements and step therapy rules change branded-to-generic conversion rates for buprenorphine/naloxone?
5. What settlement terms most often preserve branded market share in sublingual OUD products?

---

References

1. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (Accessed via FDA database).
2. FDA. Drugs@FDA. (Accessed via FDA database).

DrugChatter Q&A for ZUBSOLV

How much is zubsolv without health insurance?
Zubsolv 11 4 compared to suboxone?